News
Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $11 Price Target
23 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
20 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
20 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Stephens & Co. Reiterates Overweight on MaxCyte, Maintains $11 Price Target
13 Mar 24
News, Price Target, Reiteration, Analyst Ratings
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
13 Mar 24
News, Penny Stocks, Price Target, Small Cap, Markets, Analyst Ratings, Trading Ideas
BTIG Maintains Buy on MaxCyte, Lowers Price Target to $8
13 Mar 24
News, Price Target, Analyst Ratings
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
13 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Mar 24
Movers
MaxCyte Expects FY24 Core Business Revenue To Be Flat To 5% Growth Compared To 2023, And SPL Program-Related Revenue Is Expected To Be ~$3M; Expects To End 2024 With $175M In Total Cash, Cash Equivalents And Investments
12 Mar 24
News, Guidance
MaxCyte Q4 EPS $(0.05) Beats $(0.07) Estimate, Sales $15.66M Beat $13.09M Estimate
12 Mar 24
Earnings, News
Earnings Scheduled For March 12, 2024
12 Mar 24
Earnings
MaxCyte Earnings Preview
11 Mar 24
Earnings
Press releases
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
10 Apr 24
News, Health Care, Press Releases
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)
4 Apr 24
Biotech, News, Press Releases
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
2 Apr 24
Press Releases, General
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
4 Mar 24
News, Economics, Press Releases
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
9 Feb 24
News, Press Releases